Long‐term porcine islet graft survival in diabetic non‐human primates treated with clinically available immunosuppressants

2020 ◽  
Author(s):  
Jong‐Min Kim ◽  
So‐Hee Hong ◽  
Hyunwoo Chung ◽  
Jun‐Seop Shin ◽  
Byoung‐Hoon Min ◽  
...  
2014 ◽  
Vol 98 ◽  
pp. 356
Author(s):  
Z. Wang ◽  
J. Li ◽  
X. Chen ◽  
C. Zhang ◽  
Z. Yin ◽  
...  
Keyword(s):  

2012 ◽  
Vol 94 (10S) ◽  
pp. 712
Author(s):  
T.-S. Kim ◽  
H. S. Lee ◽  
S. Lee ◽  
S. H. Song ◽  
M. Shin ◽  
...  

2005 ◽  
Vol 14 (2-3) ◽  
pp. 85-96 ◽  
Author(s):  
Antonello Pileggi ◽  
R. Damaris Molano ◽  
Thierry Berney ◽  
Hirohito Ichii ◽  
Sergio San Jose ◽  
...  

Transplantation of islets of Langerhans in patients with type 1 diabetes allows for improved metabolic control and insulin independence. The need for chronic immunosuppression limits this procedure to selected patients with brittle diabetes. Definition of therapeutic strategies allowing permanent engraftment without the need for chronic immunosuppression could overcome such limitations. We tested the effect of the use of protoporphyrins (CoPP and FePP), powerful inducers of the cytoprotective protein hemeoxygenase 1 (HO-1), on allogeneic islet graft survival. Chemically induced diabetic C57BL/6 mice received DBA/2 islets. Treatment consisted in peritransplant administration of CoPP or saline. Islets were either cultured in the presence of FePP or vehicle before implant. Short-course administration of CoPP led to long-term islet allograft survival in a sizable proportion of recipients. Long-term graft-bearing animals rejected third-party islets while accepting a second set donor-specific graft permanently, without additional treatment. Preconditioning of islets with FePP by itself led to improved graft survival in untreated recipients, and provided additional advantage in CoPP-treated recipients, resulting in an increased proportion of long-term surviving grafts. Preconditioning of the graft with protoporphyrins prior to implant resulted in reduction of class II expression. Administration of protoporphyrins to the recipients of allogeneic islets also resulted in transient powerful immunosuppression with reduced lymphocyte proliferative responses, increased proportion of regulatory cells (CD4+CD25+), decreased mononuclear cell infiltrating the graft, paralleled by a systemic upregulation of HO-1 expression. All these mechanisms may have contributed to the induction of donor-specific hyporesponsiveness in a proportion of the protoporphyrintreated animals.


Diabetes ◽  
2004 ◽  
Vol 53 (9) ◽  
pp. 2338-2345 ◽  
Author(s):  
Q. Shi ◽  
D. Wang ◽  
G. A. Hadley ◽  
A. W. Bingaman ◽  
S. T. Bartlett ◽  
...  
Keyword(s):  
Nod Mice ◽  

2002 ◽  
Vol 73 (9) ◽  
pp. 1425-1430 ◽  
Author(s):  
Fumin Fu ◽  
Shiling Hu ◽  
Jeffrey Deleo ◽  
Shu Li ◽  
Christine Hopf ◽  
...  
Keyword(s):  

Diabetes ◽  
2007 ◽  
Vol 56 (5) ◽  
pp. 1289-1298 ◽  
Author(s):  
J. A. Emamaullee ◽  
L. Stanton ◽  
C. Schur ◽  
A.M. J. Shapiro

2008 ◽  
Vol 17 (10-11) ◽  
pp. 1243-1256 ◽  
Author(s):  
Tsunehiro Kobayashi ◽  
Hossein Arefanian ◽  
George Harb ◽  
Eric B. Tredget ◽  
Ray V. Rajotte ◽  
...  

Several studies have demonstrated that in vitro culture of islets prolonged islet graft survival in immune-competent mice without administration of antirejection drugs. However, we recently showed that in vitro cultured microencapsulated neonatal porcine islets (NPI) were rejected in immune-competent mice not receiving antirejection therapy. The aim of this study was to determine whether culture of microencapsulated NPI in vivo could promote long-term survival of microencapsulated NPI in immune-competent mice without administration of antirejection drugs. Microencapsulated NPI that were cultured in vitro for 7 and 50 days or transplanted initially in immune-deficient C.B.-17 SCID-BEIGE mice for 100 days (in vivo cultured) were characterized and transplanted into streptozotocin-induced diabetic immune-competent BALB/c mice. Day 50 in vitro cultured and day 100 in vivo cultured microencapsulated NPI showed significantly higher insulin and DNA content, indicating maturation of NPI compared to day 7 in vitro cultured microencapsulated NPI. Interestingly, in vivo cultured microencapsulated NPI expressed lower levels of porcine antigens compared to day 7 and day 50 in vitro cultured microencapsulated NPI. Transplantation of day 7 in vitro cultured microencapsulated NPI did not reverse diabetes in immune-competent BALB/c mouse recipients. In contrast, transplantation of day 50 in vitro cultured and in vivo cultured microencapsulated NPI into diabetic immune-competent BALB/c mice resulted in the immediate reversal of hyperglycemia within 2 days posttransplantation. However, all recipients of day 50 in vitro cultured microencapsulated NPI eventually rejected their grafts by day 15 posttransplantation, while 6 of 10 BALB/c mouse recipients of in vivo cultured microencapsulated NPI maintained normoglycemia for 100 days posttransplantation. These results show that in vivo culture of NPI in immune-deficient mice results in the modulation of NPI, which allows for their long-term survival in immune-competent mice without antirejection therapy.


Sign in / Sign up

Export Citation Format

Share Document